2021
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant
Lakeman IMM, van den Broek AJ, Vos JAM, Barnes DR, Adlard J, Andrulis IL, Arason A, Arnold N, Arun BK, Balmaña J, Barrowdale D, Benitez J, Borg A, Caldés T, Caligo MA, Chung WK, Claes KBM, Collée J, Couch F, Daly M, Dennis J, Dhawan M, Domchek S, Eeles R, Engel C, Evans D, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz P, Garber J, Gayther S, Gerdes A, Godwin A, Goldgar D, Hahnen E, Hake C, Hamann U, Hogervorst F, Hooning M, Hopper J, Hulick P, Imyanitov E, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Jensen U, Jiao Y, John E, Joseph V, Karlan B, Kets C, Konstantopoulou I, Kwong A, Legrand C, Leslie G, Lesueur F, Loud J, Lubiński J, Manoukian S, McGuffog L, Miller A, Gomes D, Montagna M, Mouret-Fourme E, Nathanson K, Neuhausen S, Nevanlinna H, Yie J, Olah E, Olopade O, Park S, Parsons M, Peterlongo P, Piedmonte M, Radice P, Rantala J, Rennert G, Risch H, Schmutzler R, Sharma P, Simard J, Singer C, Stadler Z, Stoppa-Lyonnet D, Sutter C, Tan Y, Teixeira M, Teo S, Teulé A, Thomassen M, Thull D, Tischkowitz M, Toland A, Tung N, van Rensburg E, Vega A, Wappenschmidt B, Devilee P, van Asperen C, Bernstein J, Offit K, Easton D, Rookus M, Chenevix-Trench G, Antoniou A, Robson M, Schmidt M. The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics In Medicine 2021, 23: 1726-1737. PMID: 34113011, PMCID: PMC8460445, DOI: 10.1038/s41436-021-01198-7.Peer-Reviewed Original ResearchConceptsCBC riskHazard ratioFirst BCC-indexPolygenic risk scoresRisk scoreConfidence intervalsContralateral breast cancer riskBreast cancer polygenic risk scoreBRCA2 pathogenic variantsAge 40 yearsBreast cancer riskMultifactorial risk modelEuropean ancestryModifiers of BRCA1/2Breast cancer risk predictionCancer risk predictionConsortium of InvestigatorsRetrospective seriesInvasive BCPathological characteristicsFamily historyEstrogen receptorHeterozygous BRCA1Cancer risk
2019
Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer
Xiao Y, Yang H, Lu J, Li D, Xu C, Risch HA. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer. BMC Cancer 2019, 19: 1020. PMID: 31664937, PMCID: PMC6819453, DOI: 10.1186/s12885-019-6250-8.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaMetastatic pancreatic ductal adenocarcinomaOverall survivalSerum GGTSignificant dose-response associationCox proportional hazards modelMetastatic PDAC patientsDose-response associationMetastatic pancreatic cancerPancreatic cancer survivalSpecialized cancer hospitalBlood glucose levelsProportional hazards modelHazard ratioPrognostic roleCancer HospitalPDAC patientsCancer survivalSubgroup analysisPancreatic cancerDuctal adenocarcinomaMetastatic PCCancer occurrenceGlucose levelsMortality riskJoint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium
Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, Odunsi K, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A, Edwards R, Goode E, Goodman M, Høgdall E, Matsuo K, Mizuno M, Nagle C, Ness R, Paddock L, Pearce C, Risch H, Rossing M, Terry K, Wu A, Modugno F, Webb P, Moysich K. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes & Control 2019, 30: 537-547. PMID: 30905014, PMCID: PMC6614876, DOI: 10.1007/s10552-019-01157-3.Peer-Reviewed Original ResearchConceptsProgression-free survivalOvarian cancer patientsOverweight/obesityBody mass indexPhysical inactivityCurrent smokingCancer patientsJoint exposureExcessive weightHazard ratioOverall survivalLifestyle factorsCox proportional hazards regression modelNormal body mass indexProportional hazards regression modelsInvasive epithelial ovarian carcinomaPurposePrevious epidemiologic studiesUnfavorable lifestyle factorsRisk of deathEpithelial ovarian carcinomaOvarian cancer survivalHazards regression modelsRisk of mortalityConfidence intervalsOvarian Cancer Association Consortium
2018
Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study
Mukhtar F, Boffetta P, Dabo B, Park JY, Tran CTD, Tran TV, Tran HT, Whitney M, Risch HA, Le LC, Zheng W, Shu XO, Luu HN. Disparities by race, age, and sex in the improvement of survival for lymphoma: Findings from a population-based study. PLOS ONE 2018, 13: e0199745. PMID: 29995909, PMCID: PMC6040734, DOI: 10.1371/journal.pone.0199745.Peer-Reviewed Original ResearchConceptsLymphoma patientsHodgkin's lymphomaAge groupsHazard ratioDisease-specific mortalityFive-year survivalHodgkin's lymphoma patientsImprovement of survivalPopulation-based studyProportional hazards regressionConfidence intervalsCause-specific mortalityIncident lymphoma casesSEER cancer registryYears of ageOlder age groupsPatients 20Surveillance EpidemiologyCancer RegistrySurvival improvementHazards regressionLymphoma casesNHL survivalPatientsLymphoma
2017
A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA
Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, Shaheen NJ, Risch HA, Vaughan TL, Wu AH, Gammon MD. A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA. International Journal Of Epidemiology 2017, 46: 1836-1846. PMID: 29040685, PMCID: PMC5837717, DOI: 10.1093/ije/dyx203.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBlood GlucoseBody Mass IndexCase-Control StudiesDietary CarbohydratesDietary SucroseEsophageal NeoplasmsFemaleGastroesophageal RefluxHumansIncidenceLogistic ModelsMaleMiddle AgedMultivariate AnalysisNutrition AssessmentProportional Hazards ModelsRisk FactorsStomach NeoplasmsUnited StatesConceptsGastro-esophageal reflux diseaseBody mass indexCarbohydrate intakeAdenocarcinoma incidenceGCA incidenceOdds ratioUS population-based case-control studyStudy-specific food-frequency questionnairesPopulation-based case-control studyCox proportional hazards regressionGlycaemic indexDietary glycaemic indexFood frequency questionnaireProportional hazards regressionCase-control studyIntake of sucroseHigh glycaemic indexCarbohydrate measuresFrequency questionnaireHazard ratioReflux diseaseMass indexHazards regressionVital statusPooled analysisHistory of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium
Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, Ness RB, LaMonte MJ, Friel G, Segal BH, Odunsi K, Mayor P, Zsiros E, Schmalfeldt B, Klapdor R, Dӧrk T, Hillemanns P, Kelemen LE, Kӧbel M, Steed H, de Fazio A, on behalf of the Australian Ovarian Cancer Study Group, Jordan SJ, Nagle CM, Risch HA, Rossing MA, Doherty JA, Goodman MT, Edwards R, Matsuo K, Mizuno M, Karlan BY, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Terry KL, Cramer DW, Bandera EV, Paddock LE, Kiemeney LA, Massuger LF, Kupryjanczyk J, Berchuck A, Chang-Claude J, Diergaarde B, Webb PM, Moysich KB, on behalf of the Ovarian Cancer Association Consortium. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes & Control 2017, 28: 469-486. PMID: 28293802, PMCID: PMC5500209, DOI: 10.1007/s10552-017-0867-1.Peer-Reviewed Original ResearchConceptsProgression-free survivalUse of diureticsHistory of hypertensionOral antidiabetic medicationsHazard ratioOvarian cancer patientsOvarian Cancer Association ConsortiumOverall survivalHistological subtypesHeart diseaseAntidiabetic medicationsBeta blockersConfidence intervalsCancer patientsCox proportional hazards regression modelOvarian cancer patient survivalProportional hazards regression modelsInvasive epithelial ovarian carcinomaOverall study populationEpithelial ovarian carcinomaUse of medicationsHazards regression modelsRisk of mortalityCancer patient survivalOvarian cancer diagnosisEpidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer
Kim SJ, Rosen B, Fan I, Ivanova A, McLaughlin JR, Risch H, Narod SA, Kotsopoulos J. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. British Journal Of Cancer 2017, 116: 964-971. PMID: 28208158, PMCID: PMC5379147, DOI: 10.1038/bjc.2017.35.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedCanadaCystadenocarcinoma, SerousEndometrial NeoplasmsEpidemiologic FactorsFemaleFollow-Up StudiesHormone Replacement TherapyHumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingOvarian NeoplasmsParityPregnancyPrognosisReproductive HistoryYoung AdultConceptsOvarian cancer-specific mortalityCancer-specific mortalityHormone replacement therapyRisk of deathEpithelial ovarian cancerOvarian cancerHazard ratioEpidemiologic factorsOvulatory cyclesOvarian cancer-specific deathOvarian cancer-specific survivalInvasive epithelial ovarian cancerBMI 5 yearsCancer-specific survivalCancer-specific deathOntario Cancer RegistryProportional hazards regressionConfidence intervalsBorderline significant associationOvarian cancer developmentLong-term survivalGreater cumulative numberHRT useCancer RegistryHistologic subtypeCigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies
Præstegaard C, Jensen A, Jensen SM, Nielsen TS, Webb PM, Nagle CM, DeFazio A, Group O, Høgdall E, Rossing M, Doherty J, Wicklund K, Goodman M, Modugno F, Moysich K, Ness R, Edwards R, Matsuo K, Hosono S, Goode E, Winham S, Fridley B, Cramer D, Terry K, Schildkraut J, Berchuck A, Bandera E, Paddock L, Massuger L, Wentzensen N, Pharoah P, Song H, Whittemore A, McGuire V, Sieh W, Rothstein J, Anton‐Culver H, Ziogas A, Menon U, Gayther S, Ramus S, Gentry‐Maharaj A, Wu A, Pearce C, Pike M, Lee A, Sutphen R, Chang‐Claude J, Risch H, Kjaer S, Consortium O. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal Of Cancer 2017, 140: 2422-2435. PMID: 28063166, PMCID: PMC5489656, DOI: 10.1002/ijc.30600.Peer-Reviewed Original ResearchConceptsPooled hazard ratioCigarette smokingOvarian Cancer Association ConsortiumOvarian cancerHazard ratioPooled analysisStudy-specific hazard ratiosLarge pooled analysisMucinous ovarian tumorsOvarian cancer stageEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsOvarian cancer prognosisCase-control studyRandom-effects modelPotential clinical importanceMedian followAdverse survivalCurrent smokingDisseminated diseaseFormer smokersWorse survivalModifiable factorsOvarian tumors
2016
Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium
Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM, Berchuck A, Chang-Claude J, Cramer DW, DeFazio A, Diergaarde B, Dörk T, Doherty JA, Edwards RP, Fridley BL, Friel G, Goode EL, Goodman MT, Hillemanns P, Hogdall E, Hosono S, Kelley JL, Kjaer SK, Klapdor R, Matsuo K, Odunsi K, Nagle CM, Olsen CM, Paddock LE, Pearce CL, Pike MC, Rossing MA, Schmalfeldt B, Segal BH, Szamreta EA, Thompson PJ, Tseng CC, Vierkant R, Schildkraut JM, Wentzensen N, Wicklund KG, Winham SJ, Wu AH, Modugno F, Ness RB, Jensen A, Webb PM, Terry K, Bandera EV, Moysich KB, on behalf of The Australian Ovarian Cancer Study Group. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2016, 115: 95-101. PMID: 27299959, PMCID: PMC4931371, DOI: 10.1038/bjc.2016.153.Peer-Reviewed Original ResearchConceptsRecreational physical activityOvarian Cancer Association ConsortiumInvasive EOCHazard ratioPhysical inactivityPooled analysisPhysical activityEpithelial ovarian cancer survivalWeekly recreational physical activityInvasive epithelial ovarian cancerCox proportional hazards modelLarge pooled analysisRecreational physical inactivityPhysical activity guidelinesEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsHigher mortality riskProportional hazards modelActivity guidelinesResidual diseaseCancer survivalPrimary diagnosisOvarian cancerInactive women
2015
Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching P, Beckmann M, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch H, Rossing M, Doherty J, Wicklund K, Chang-Claude J, Goodman M, Ness R, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode E, Vierkant R, Larson M, Fridley B, Høgdall C, Schildkraut J, Weber R, Cramer D, Terry K, Bandera E, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang H, Brinton L, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce C, Wu A, Webb P. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal Of Cancer 2015, 113: 817-826. PMID: 26151456, PMCID: PMC4559823, DOI: 10.1038/bjc.2015.245.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexOvarian cancer-specific survivalCancer-specific survivalOvarian cancerHazard ratioHistologic subtypeOverall survivalHigh-grade serous cancerHigher Body Mass IndexInvasive ovarian cancerPooled hazard ratioDifferent histologic subtypesOvarian Cancer Association ConsortiumMajority of womenRandom-effects modelAdverse survivalPooled HRsSerous cancerEndometrioid subtypeMass indexOvarian carcinomaObservational studyModest associationCancerOvarian cancer survival by tumor dominance, a surrogate for site of origin
Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. Cancer Causes & Control 2015, 26: 601-608. PMID: 25771796, PMCID: PMC4561551, DOI: 10.1007/s10552-015-0547-y.Peer-Reviewed Original ResearchConceptsDominant tumorHazard ratioFallopian tubeEstrogen hormone replacement therapyConclusionThese preliminary findingsHormone replacement therapyDistal fallopian tubeRisk of deathEpithelial ovarian cancerOvarian cancer survivalConfidence intervalsProportional hazards modelSite of originTubal originWorse survivalReplacement therapyOvarian tumorsCancer survivalOvarian cancerPathology reportsOnly subtypeBRCA1/2 mutationsHazards modelObjectivesRecent studiesTumorsDietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA)
Petrick JL, Steck SE, Bradshaw PT, Trivers KF, Abrahamson PE, Engel LS, He K, Chow WH, Mayne ST, Risch HA, Vaughan TL, Gammon MD. Dietary intake of flavonoids and oesophageal and gastric cancer: incidence and survival in the United States of America (USA). British Journal Of Cancer 2015, 112: 1291-1300. PMID: 25668011, PMCID: PMC4385952, DOI: 10.1038/bjc.2015.25.Peer-Reviewed Original ResearchConceptsOdds ratioHazard ratioFlavonoid intakeGastric cancerFood frequency questionnaire responsesMulticentre population-based studyIntake of anthocyanidinsLowest intake quartilesTotal flavonoid intakeFrequency-matched controlsPopulation-based studyProportional hazards regressionRisk of mortalityUSDA flavonoid databasesCase participantsAnthocyanidin intakeIntake quartilesHazards regressionVital statusDietary intakeChemopreventive effectsEpidemiologic studiesTumor typesFlavonoid databaseCancerPrognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. European Journal Of Gynaecological Oncology 2015, 36: 260-7. PMID: 26189250.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdultAgedBiomarkers, TumorCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPhosphoric Monoester HydrolasesPrognosisProportional Hazards ModelsPTEN PhosphohydrolaseTumor Suppressor Protein p53Young AdultConceptsAberrant p53 expressionOvarian cancerP53 expressionHazard ratioLoss of PTENOvarian tumorsOvarian cancer tissue samplesEndometrioid ovarian tumorsProtein expressionSurvival hazard ratioEpithelial ovarian tumorsPoor disease outcomePossible prognostic roleProportional hazards modelCancer tissue samplesPrognostic roleEndometrioid tumorsEndometrioid subtypePrognostic valuePoor prognosisSerous subtypeProtein immunohistochemistryDisease outcomeTissue microarrayHazards modelSurvival in women with ovarian cancer with and without microsatellite instability.
Segev Y, Zhang S, Akbari MR, Sun P, Sellers TA, McLaughlin J, Risch HA, Rosen B, Shaw P, Schildkraut J, Narod SA, Pal T. Survival in women with ovarian cancer with and without microsatellite instability. European Journal Of Gynaecological Oncology 2015, 36: 681-4. PMID: 26775351.Peer-Reviewed Original ResearchConceptsPresence of MSIEpithelial ovarian cancerOvarian cancerMicrosatellite instabilityPrognostic factorsMSI statusNational Cancer Institute criteriaSpecific prognostic factorsPopulation-based studyOvarian cancer patientsHazard ratioPathologic featuresCancer patientsSubgroup analysisDefective mismatch repairSurvival differencesMulti-variate analysisCancerTumor samplesMSI markersSignificant differencesPatientsSurvivalWomenMismatch repair
2013
The Healthy Eating Index 2005 and Risk for Pancreatic Cancer in the NIH–AARP Study
Arem H, Reedy J, Sampson J, Jiao L, Hollenbeck AR, Risch H, Mayne ST, Stolzenberg-Solomon RZ. The Healthy Eating Index 2005 and Risk for Pancreatic Cancer in the NIH–AARP Study. Journal Of The National Cancer Institute 2013, 105: 1298-1305. PMID: 23949329, PMCID: PMC3760780, DOI: 10.1093/jnci/djt185.Peer-Reviewed Original ResearchConceptsHealthy Eating Index 2005Pancreatic cancer riskPancreatic cancerHazard ratioDietary guidelinesCancer riskExocrine pancreatic cancer casesOverweight/obese menCox proportional hazards regressionHealth-American AssociationP-interaction valuesRetired Persons DietFood frequency questionnaireNormal-weight menDietary pattern analysisBody mass indexProportional hazards regressionConfidence intervalsPancreatic cancer casesNIH-AARP studyFrequency questionnaireObese menMass indexHazards regressionWeight menLong-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2
McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2. Journal Of The National Cancer Institute 2013, 105: 141-148. PMID: 23257159, PMCID: PMC3611851, DOI: 10.1093/jnci/djs494.Peer-Reviewed Original ResearchConceptsInvasive ovarian cancerOvarian cancerBRCA2 mutationsLong-term survival benefitOvarian cancer-specific survivalCancer-specific survivalOvarian cancer survivalSerous ovarian cancerShort-term survival advantageBRCA1 mutation carriersLong-term survivalHazard ratioSurvival benefitBetter prognosisUnselected womenBRCA2 carriersCancer survivalMutation carriersSurvival advantageSurvival analysisCancerDiagnosisTime pointsWomenSurvivalFlavonoid intake and risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study Cohort
Arem H, Bobe G, Sampson J, Subar AF, Park Y, Risch H, Hollenbeck A, Mayne ST, Stolzenberg-Solomon RZ. Flavonoid intake and risk of pancreatic cancer in the National Institutes of Health-AARP Diet and Health Study Cohort. British Journal Of Cancer 2013, 108: 1168-1172. PMID: 23299536, PMCID: PMC3619057, DOI: 10.1038/bjc.2012.584.Peer-Reviewed Original ResearchConceptsPancreatic cancer riskHealth-AARP DietHealth Study cohortFlavonoid intakeCancer riskHazard ratioStudy cohortTotal flavonoid intakeDietary flavonoid intakeIntake of flavonoidsProspective National InstitutesConfidence intervalsPancreatic cancer casesCox proportional hazardsNational InstitutePancreatic cancer carcinogenesisLimited epidemiological studiesSmoking statusInverse associationPancreatic cancerCancer carcinogenesisCancer casesEpidemiological studiesProportional hazardsProtective role
2012
Height, weight, BMI and ovarian cancer survival
Kotsopoulos J, Moody JR, Fan I, Rosen B, Risch HA, McLaughlin JR, Sun P, Narod SA. Height, weight, BMI and ovarian cancer survival. Gynecologic Oncology 2012, 127: 83-87. PMID: 22713293, DOI: 10.1016/j.ygyno.2012.05.038.Peer-Reviewed Original ResearchConceptsBody mass indexOvarian cancer survivalOvarian cancer-specific mortalityCancer-specific mortalityHazard ratioCancer survivalOvarian cancerLarge population-based studyBMI 5 yearsFatal gynecologic malignancyPopulation-based studyEpithelial ovarian cancerConfidence intervalsOvarian cancer prognosisProportional hazards modelChart reviewGynecologic malignanciesClinicopathologic featuresHistologic subtypeMass indexVital statusModifiable factorsRisk factorsHazards modelCancer prognosis
2005
Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers
Trivers KF, de Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clinical Gastroenterology And Hepatology 2005, 3: 225-230. PMID: 15765441, DOI: 10.1016/s1542-3565(04)00613-5.Peer-Reviewed Original ResearchConceptsBody mass indexEsophageal squamous cell carcinomaGastric cancerHazard ratioLonger survivalNonsteroidal anti-inflammatory drug usePopulation-based case-control studyAnti-inflammatory drug usePrediagnosis body mass indexAdjusted hazard ratioGastroesophageal reflux diseaseSquamous cell carcinomaConfidence intervalsGastric cancer survivalCase-control studyEsophageal adenocarcinoma patientsLocalized diseaseReflux diseaseMass indexAlcohol intakeCigarette smokingDecreased riskIncident casesAdenocarcinoma patientsCell carcinoma